-
Product Insights
Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat....
-
Product Insights
Metastatic Hepatocellular Carcinoma (HCC) - Drugs In Development, 2024
Empower your strategies with our Metastatic Hepatocellular Carcinoma (HCC) – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic hepatocellular carcinoma (HCC) refers to liver cancer that has spread to other parts of the body. It originates in liver cells and often spreads to the lungs, bones, lymph nodes, or other organs. Symptoms at this stage can include jaundice, abdominal pain, weight loss, and fatigue. Treatment options for metastatic HCC involve a combination of therapies, such as targeted...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2024
Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a...
-
Product Insights
Ewing Sarcoma - Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
Malignant Pleural Mesothelioma - Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
High-Grade Glioma - Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Product Insights
Ocular Melanoma - Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
Anaplastic Large Cell Lymphoma (ALCL) - Drugs In Development, 2024
Empower your strategies with our Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma, involving abnormal growth of immune cells called lymphocytes. ALCL can affect the lymph nodes, skin, and other organs, often presenting as swollen lymph nodes or skin lumps. Two main subtypes exist: one linked to a genetic mutation and the other associated with breast implants. Treatment...
-
Product Insights
Hypopharyngeal Cancer - Drugs In Development, 2024
Empower your strategies with our Hypopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end...
-
Product Insights
Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.